Mylan has biosimilar aspirations for Botox

Mylan is teaming up with California-based biotechnology firm Revance Therapeutics to develop and commercialise a biosimilar of Allergan’s world-renowned Botox (onabotulinumtoxinA) injection, as part of Mylan’s long-term strategy to bring to market complex products and biosimilars, as well as to gain traction in the growing global market for neuromodulators.

Mylan is teaming up with California-based biotechnology firm Revance Therapeutics to develop and commercialise a biosimilar of Allergan’s world-renowned Botox (onabotulinumtoxinA) injection, as part of Mylan’s long-term strategy to bring to market complex products and biosimilars, as well as to gain traction in the growing global market for neuromodulators.

Under the firms’ global collaboration and license agreement, Mylan and Revance plan to work together to gain regulatory approval in the development of this “important biosimilar product”, and commercialise the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.

Is Towa’s Guidance For 2024 ‘Somewhat Mediocre?’

 
• By 

Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.

Publisher’s Spotlight: Citeline News And Insights App

 
• By 

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from Generics Bulletin

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By 

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By 

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.

Abiogen And mAbxience Join Forces In Italy

 
• By 

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.